These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 9808576)

  • 1. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
    Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
    Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.
    Li S; Gillessen S; Tomasson MH; Dranoff G; Gilliland DG; Van Etten RA
    Blood; 2001 Mar; 97(5):1442-50. PubMed ID: 11222392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
    J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype.
    Zhang X; Wong R; Hao SX; Pear WS; Ren R
    Blood; 2001 Jan; 97(1):277-87. PubMed ID: 11133772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo.
    Jiang X; Ng E; Yip C; Eisterer W; Chalandon Y; Stuible M; Eaves A; Eaves CJ
    Blood; 2002 Nov; 100(10):3731-40. PubMed ID: 12393460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
    Wolff NC; Ilaria RL
    Blood; 2001 Nov; 98(9):2808-16. PubMed ID: 11675355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease progression in a murine model of bcr/abl leukemogenesis.
    van Etten RA
    Leuk Lymphoma; 1993; 11 Suppl 1():239-42. PubMed ID: 8251903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.
    Hao SX; Ren R
    Mol Cell Biol; 2000 Feb; 20(4):1149-61. PubMed ID: 10648600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia.
    Salesse S; Verfaillie CM
    Mol Cancer Ther; 2003 Feb; 2(2):173-82. PubMed ID: 12589034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
    Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.
    Gross AW; Zhang X; Ren R
    Mol Cell Biol; 1999 Oct; 19(10):6918-28. PubMed ID: 10490629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias.
    Honda H; Oda H; Suzuki T; Takahashi T; Witte ON; Ozawa K; Ishikawa T; Yazaki Y; Hirai H
    Blood; 1998 Mar; 91(6):2067-75. PubMed ID: 9490692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Src homology-2 protein Shb modulates focal adhesion kinase signaling in a BCR-ABL myeloproliferative disorder causing accelerated progression of disease.
    Gustafsson K; Jamalpour M; Trinh C; Kharas MG; Welsh M
    J Hematol Oncol; 2014 Jun; 7():45. PubMed ID: 24952416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector.
    Zhao RC; Jiang Y; Verfaillie CM
    Blood; 2001 Apr; 97(8):2406-12. PubMed ID: 11290604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice.
    Gishizky ML; Johnson-White J; Witte ON
    Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3755-9. PubMed ID: 8475126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3.
    Tomasson MH; Williams IR; Li S; Kutok J; Cain D; Gillessen S; Dranoff G; Van Etten RA; Gilliland DG
    Blood; 2001 Mar; 97(5):1435-41. PubMed ID: 11222391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
    He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
    Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
    Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
    Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.